Surface Low-Grade Cartilage Malignancy
- PERIOSTEAL (juxtacortical) CHONDROSARCOMA is a rare malignant CARTILAGE tumour arising on the bone SURFACE (from the periosteum/cortex) rather than within the medullary cavity; it most often involves the METAPHYSIS of the long bones of the extremities. In the largest single-centre series (Rizzoli, n = 55; median age 37, 62% male, median size 7.5 cm) only 42% were grade 1 - 49% were grade 2, 5% grade 3 and 4% dedifferentiated - so 'low-grade' in practice means 'grade 1 OR 2'.
- Behaviour is indolent but not benign. Over a median 137 months in 54 followed patients there were 4 local recurrences (7.4%) and 6 lung metastases (11.1%); ALL SIX who metastasised DIED OF DISEASE, while 46 (85%) were alive without disease. Neither grade nor any other clinical or morphological parameter was statistically associated with overall or disease-free survival - so you cannot reassure a patient on the basis of a grade 1 biopsy.
- A proportion of periosteal chondrosarcomas harbour IDH1 mutations (as in other cartilage tumours), which can support the diagnosis on molecular testing; the lesion shows a chondroid (cartilage) matrix on imaging, with cortical scalloping/thickening and a surface soft-tissue mass.
- The key DIFFERENTIAL is from the benign PERIOSTEAL CHONDROMA (a small, benign surface cartilage tumour, usually a few centimetres) and from PERIOSTEAL (surface) OSTEOSARCOMA - distinction rests on size and aggressiveness, the matrix (chondroid in chondrosarcoma vs osteoid in osteosarcoma), and the histological grade; a periosteal chondroma that is large or aggressive should raise concern for chondrosarcoma.
- DIAGNOSIS requires imaging (radiograph/CT for the chondroid matrix and cortical changes, MRI for extent) and a properly PLANNED BIOPSY read at a specialist centre, with staging where indicated; as with all bone sarcomas, an unplanned excision must be avoided.
- MANAGEMENT is adequate surgical EXCISION, and cartilage tumours are relatively CHEMO/RADIO-RESISTANT, so surgery is the mainstay. Know the caveat the literature's own headline hides: the Rizzoli authors conclude that periosteal chondrosarcoma 'can be adequately treated with marginal excision', but in their own cohort the margin was WIDE OR RADICAL in 38 of 54 (70.4%) and marginal in only 9 (16.7%), with 7 (12.9%) intralesional - so the good survival was achieved predominantly under WIDE margins, and 'marginal is enough' is an inference from a small subgroup, not a tested comparison.
- “Periosteal chondrosarcoma = rare SURFACE (juxtacortical) malignant cartilage tumour, usually LOW-grade, at the METAPHYSIS of long bones. Chondroid matrix; cortical scalloping; IDH1 in a proportion.
- “Rizzoli n = 55: 42% grade 1, 49% grade 2. At median 137 months - 4 local recurrences (7.4%), 6 lung metastases (11.1%), all six dead of disease; 85% alive without disease. NO parameter, grade included, predicted survival.
- “Differential: benign periosteal chondroma (small) vs surface osteosarcoma (osteoid matrix). Treatment = adequate EXCISION; chemo/radio-resistant. The 'marginal excision is adequate' conclusion comes from a cohort in which 70.4% actually had WIDE/radical margins.
Overview and Behaviour
Periosteal, or juxtacortical, chondrosarcoma is a rare malignant cartilage tumour that arises on the bone surface, from the periosteum and cortex, rather than within the medullary cavity. It typically involves the metaphysis of a long bone of the extremities, the femur or humerus, and presents as a surface mass with a cartilaginous (chondroid) matrix.
Grade. The great majority are low or intermediate grade. In the largest single-centre series (Rizzoli, n = 55), though, only 42% were grade 1, so "low-grade" in practice means grade 1 or 2.
Behaviour. It is generally indolent with a good overall prognosis, but it is not benign. In that series 11% developed lung metastases and every one of those patients died of disease, and no parameter, grade included, predicted who they would be.
Imaging: Periosteal Chondroma versus Periosteal Chondrosarcoma
Radiographs and CT show the chondroid matrix and the cortical changes. Both lesions are surface cartilage tumours with ring-and-arc matrix and cortical scalloping, and they overlap radiographically. The features that separate them:
- Periosteal chondroma
- Small, usually under about 3 cm
- Periosteal chondrosarcoma
- Larger, typically over 5 cm (median 7.5 cm across the 55-case Rizzoli series)
- Periosteal chondroma
- Well-defined, saucer-shaped defect (scalloping) with a sclerotic rim and a solid periosteal buttress at its margins
- Periosteal chondrosarcoma
- More aggressive or irregular scalloping and thickening, sometimes frank cortical destruction
- Periosteal chondroma
- No significant soft-tissue mass
- Periosteal chondrosarcoma
- Larger, bulkier soft-tissue mass
- Periosteal chondroma
- Chondroid ring-and-arc mineralisation
- Periosteal chondrosarcoma
- Ring-and-arc mineralisation; more extensive, irregular mineralisation favours chondrosarcoma
MRI. The hyaline cartilage gives lobulated high T2 signal, and MRI shows the true extent of the lesion, including any medullary involvement.
The marrow. Both are surface lesions and typically spare the medullary cavity, so any medullary permeation is worrying.
Where imaging stops. Larger size, aggressive cortical change and a soft-tissue mass raise suspicion for chondrosarcoma. The grade and the definitive diagnosis are settled on a planned biopsy at a sarcoma unit.
Biopsy, Grade and the IDH Mutation
The biopsy. The diagnosis and grade must be established on a properly planned biopsy read at a specialist centre, with staging where indicated, before definitive surgery. As with all bone sarcomas, an unplanned excision of an undiagnosed surface mass compromises the eventual oncological result.
The mutation. IDH1 and IDH2 encode isocitrate dehydrogenase. In cartilage tumours they carry heterozygous gain-of-function point mutations, classically at IDH1 codon 132, that make the enzyme produce the oncometabolite 2-hydroxyglutarate (2-HG), which dysregulates DNA and histone methylation and drives abnormal chondrogenesis.
Where it is found. About half of conventional central chondrosarcomas and enchondromas carry an IDH1 or IDH2 mutation, as do the enchondromatoses (Ollier disease and Maffucci syndrome). In periosteal chondrosarcoma the figure is roughly a third, but only of the cases in which mutational analysis was technically feasible. The true rate across the whole cohort is therefore unknown, and a negative result never excludes the diagnosis.
What it adds. Detecting an IDH mutation helps confirm that a lesion is a cartilage tumour and helps distinguish it from IDH-wild-type mimics, notably chondroblastic osteosarcoma and chordoma. IDH is also a therapeutic target, with IDH inhibitors in use or in trials for IDH-mutant tumours.
Differential Diagnosis
The two main alternatives on the bone surface are the benign periosteal chondroma and surface (periosteal) osteosarcoma. The distinction rests on size and aggressiveness, the matrix (chondroid in chondrosarcoma, osteoid in osteosarcoma) and the histology.
- Nature
- Benign
- Key features
- Small surface cartilage tumour; saucerised cortex
- Nature
- Malignant (usually low-grade)
- Key features
- Larger, metaphyseal, chondroid matrix, cortical scalloping; IDH1 in a proportion
- Nature
- Malignant (intermediate-grade)
- Key features
- Diaphyseal, chondroblastic but osteoid-producing
The two pitfalls. A benign periosteal chondroma that is large or behaves aggressively should raise concern for chondrosarcoma. A surface lesion that produces osteoid is a surface osteosarcoma.
Management
Surgery. In the great majority of cases this is a grade 1-2 surface malignancy that behaves indolently and is cured by adequate surgical excision. Because cartilage tumours are relatively resistant to chemotherapy and radiotherapy, surgery is the mainstay.
The Rizzoli series concluded that marginal excision is adequate, yet it achieved its results with wide or radical margins in 70.4% of patients, and its own analysis found no clinical or pathological parameter that predicted survival. Grade therefore cannot be used to justify accepting a close margin.
Where the series disagree. The other sizeable series, from Mayo, points the other way: there margin width tracked local control and grade tracked metastasis (see the evidence below). Both "marginal is adequate" and "grade does not predict" are contested, and no trial of margin width exists, so aim for a clear margin.
Mnemonics & Memory Aids
CHONDRAL
Hook:CHONDRAL: Cartilage matrix, differential (chondroma/sarcoma/osteosarcoma), Often low-grade, Near metaphysis, Diagnose+grade, Resect to a clear margin, chemo/radio-resistant.
SURFACE
Hook:SURFACE: Surface mass, Usually low-grade, Rizzoli good-prognosis-but-fatal-tail, Failing margins recur, All metastases died, Chemo-resistant, Excise to a clear margin.
GRADE
Hook:GRADE: Grade but don't trust it, Rind signature, All metastases died, Distinguish the mimics, Every patient surveilled.
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“How do you approach a surface cartilage lesion at the metaphysis of the femur reported as a possible periosteal chondrosarcoma?”
What it is
- Rare surface (juxtacortical) malignant cartilage tumour
- Usually low/intermediate grade; metaphysis of long bones
- Chondroid matrix + cortical scalloping; IDH1 in a proportion
Behaviour & differential
- Rizzoli n = 55, median follow-up 137 months: 7.4% local recurrence, 11.1% lung metastasis, all six metastatic patients dead; 85% alive without disease
- No clinical or pathological parameter - grade included - predicted survival
- Differential: benign periosteal chondroma (small); surface osteosarcoma (osteoid)
Management
- Planned biopsy + grade at a sarcoma unit; stage as indicated
- Adequate excision aiming at a clear margin; 70.4% of the published series had wide/radical margins
- 'Marginal excision is adequate' is a conclusion, not a tested comparison - no trial of margin width exists
- Cartilage tumours chemo/radio-resistant - surgery is the mainstay
Evidence & Key Studies
Periosteal chondrosarcoma: a case series with survivorship analysis
- 55 periosteal chondrosarcomas from a single Italian referral centre (Rizzoli), retrospective. Median age 37 years, 62% male, median tumour size 7.5 cm; the great majority involved the metaphysis of long bones of the extremities. Grade: 23 (42%) grade 1, 27 (49%) grade 2, 3 (5%) grade 3, 2 (4%) dedifferentiated.
- Surgery: 30 subtotal resection, 22 tangential resection, 3 amputation. Margins (reported in 54): wide/radical 38 (70.4%), marginal 9 (16.7%), intralesional 7 (12.9%) - so the cohort behind the 'marginal is adequate' conclusion was predominantly widely resected.
- Outcome at median 137 months in 54 followed patients: 4 local recurrences (7.4%), 6 lung metastases (11.1%). All six who metastasised died of disease; 2 died of unrelated causes; 46 (85%) alive without disease. Heterozygous IDH1 codon 132 mutations in a third of the cases in which analysis was feasible.
- Neither overall nor disease-free survival was statistically associated with any clinical or pathological parameter considered - including grade. Limitations: single centre, retrospective, no comparison of margin strategies, and event numbers (4 and 6) far too small to power the prognostic analysis, so 'no predictor' means underpowered rather than proven absent.
This is the sentence most likely to be quoted back at you, and the one most likely to be misused. It is the authors' conclusion, not their protocol. Their 54 margin-reported patients were resected wide or radical in 70.4%, marginal in 16.7% and intralesional in 12.9% - there was no comparison of one margin strategy against another, and with only 4 recurrences and 6 metastases the study had no power to detect a difference if one existed. The defensible answer in a viva is: periosteal chondrosarcoma behaves indolently enough that a planned marginal excision achieving a clear margin may suffice for a small grade 1 lesion at a sarcoma unit, but the published survival was obtained mostly under wide margins, and since no parameter - grade included - predicted which patients would metastasise and die, the burden of proof sits with the surgeon proposing the smaller resection.
Survivorship analysis in patients with periosteal chondrosarcoma
- 24 consecutive patients (17 male, mean age 37.6 years); femur in 12, proximal humerus in 5; mean size 8.1 cm; 18 grade 1 and 6 grade 2 tumours.
- Five-year local recurrence-free survival was 25% after intralesional or marginal excision versus 93% after wide resection; 7 of 24 (29%) recurred.
- Six of 24 (25%) died of pulmonary metastases; 5-year metastasis-free survival 83% overall, 50% for grade 2 versus 94% for grade 1.
Periosteal chondroma
- The classic description of the benign counterpart - the periosteal chondroma (juxtacortical chondroma) - from the Enneking unit.
- A small, surface, chondroid lesion with cortical saucerisation and a sclerotic rim - the imaging contrast to periosteal chondrosarcoma, which is larger and destructive.
- Pre-dates modern cross-sectional imaging; the size-and-aggressiveness distinction it draws remains the practical separator.
Every figure quoted above - n = 55, median age 37, 62% male, median size 7.5 cm, the grade distribution, the operation and margin counts, the 4 local recurrences and 6 fatal lung metastases at median 137 months, the IDH1 codon 132 rate, and the absence of any surviving prognostic parameter - comes from the cited Pacheco series (DOI). The classic description of the benign periosteal chondroma comes from the cited Rockwell/Enneking paper, and the conflicting survivorship data (margin and grade mattered in the Mayo cohort: 25% versus 93% recurrence-free, 50% versus 94% metastasis-free) from the cited Papagelopoulos series - which the ExamWarning on this page must be read against. The distinction from surface osteosarcoma, the chemo/radio-resistance of cartilage tumours, and the biopsy/staging principles are standard, well-established teaching. No randomised or comparative trial of margin width exists in this tumour, and no validated surveillance interval or risk score has been published for it.